HUP0104943A2 - Controlled release formulation comprising gnrh-ii and its use - Google Patents

Controlled release formulation comprising gnrh-ii and its use

Info

Publication number
HUP0104943A2
HUP0104943A2 HU0104943A HUP0104943A HUP0104943A2 HU P0104943 A2 HUP0104943 A2 HU P0104943A2 HU 0104943 A HU0104943 A HU 0104943A HU P0104943 A HUP0104943 A HU P0104943A HU P0104943 A2 HUP0104943 A2 HU P0104943A2
Authority
HU
Hungary
Prior art keywords
gnrh
controlled release
release formulation
formulation
controlled
Prior art date
Application number
HU0104943A
Other languages
Hungarian (hu)
Inventor
Karen Akinsanya
Amanda Hayward
Steve Qi
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HUP0104943A2 publication Critical patent/HUP0104943A2/en
Publication of HUP0104943A3 publication Critical patent/HUP0104943A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HU0104943A 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii and its use HUP0104943A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation

Publications (2)

Publication Number Publication Date
HUP0104943A2 true HUP0104943A2 (en) 2002-06-29
HUP0104943A3 HUP0104943A3 (en) 2002-08-28

Family

ID=10843631

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104943A HUP0104943A3 (en) 1998-12-03 1999-12-02 Controlled release formulation comprising gnrh-ii and its use

Country Status (22)

Country Link
EP (1) EP1140133A1 (en)
JP (1) JP2002531411A (en)
KR (1) KR20010089538A (en)
CN (1) CN1332635A (en)
AU (1) AU770676B2 (en)
BR (1) BR9915943A (en)
CA (1) CA2353798A1 (en)
CZ (1) CZ20011893A3 (en)
EE (1) EE200100293A (en)
GB (1) GB2344287A (en)
HR (1) HRP20010421A2 (en)
HU (1) HUP0104943A3 (en)
IL (1) IL143496A0 (en)
MX (1) MXPA01005543A (en)
NO (1) NO20012636L (en)
NZ (1) NZ511984A (en)
PL (1) PL348575A1 (en)
RU (1) RU2233170C2 (en)
SK (1) SK7552001A3 (en)
TR (1) TR200102273T2 (en)
WO (1) WO2000032218A1 (en)
ZA (1) ZA200104530B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334258B2 (en) 2005-07-26 2012-12-18 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (Universitätsmedizin) Method for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
CN102448482A (en) 2009-03-27 2012-05-09 范安德尔研究所 Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
US20120208762A1 (en) 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
MX2012008603A (en) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity.
ES2575160T3 (en) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibitors of the interactions that bind the alpha subunit of beta integrin-protein G
CA2802485C (en) 2010-06-16 2019-09-17 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US20120004182A1 (en) 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
BR112013015389A2 (en) 2010-12-22 2016-11-22 Univ Indiana Res & Tech Corp glucagon analog displaying gip receptor activity
CN103857408B (en) 2011-06-22 2017-04-12 印第安那大学科技研究公司 Glucagon/glp-1 receptor co-agonists
US9415123B2 (en) 2011-10-10 2016-08-16 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
RU2014117678A (en) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon superfamily peptides with glucocorticoid receptor activity
JP6392123B2 (en) 2011-12-20 2018-09-19 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ CTP-based insulin analog for diabetes treatment
AU2013274078A1 (en) 2012-06-14 2015-01-29 Ambrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
JP6300239B2 (en) 2012-06-21 2018-03-28 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analog showing GIP receptor activity
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
US20160024169A1 (en) 2013-03-14 2016-01-28 Indiana University Research And Technology Corporation Insulin-incretin conjugates
WO2015120187A1 (en) 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
US10308719B2 (en) 2015-01-26 2019-06-04 The University Of Chicago IL13Rα2 binding agents and use thereof in cancer treatment
WO2016123143A1 (en) 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
CN104789524A (en) * 2015-04-30 2015-07-22 四川大学 Osteoporotic rat primary osteoblasts isolated culture method and application thereof
WO2017024111A1 (en) 2015-08-04 2017-02-09 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
JP2020505379A (en) * 2017-01-20 2020-02-20 イミューン システム レギュレェイション ホールディング エービー Novel compound (immunorelin)
AU2018290983B2 (en) 2017-06-30 2023-11-23 Amgen Inc. Methods of treating heart failure with cardiac sarcomere activators
CN118126157A (en) 2017-08-03 2024-06-04 美国安进公司 Interleukin-21 muteins and methods of treatment
EP4141005B1 (en) 2017-09-08 2024-04-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
GB202103867D0 (en) 2017-09-18 2021-05-05 Univ California Claudin6 antibodies and methods of treating cancer
TW201930344A (en) 2018-01-12 2019-08-01 美商安進公司 Anti-PD-1 antibodies and methods of treatment
US20200085776A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of Reducing C-Reactive Protein and/or Treating Cardiovascular Disease
EP3941944A4 (en) 2019-03-20 2022-11-30 The Regents of the University of California Claudin-6 bispecific antibodies
MX2021011330A (en) 2019-03-20 2021-12-10 Univ California Claudin-6 antibodies and drug conjugates.
CA3102364A1 (en) * 2019-03-26 2020-10-01 Novel Pharma Inc. Long-acting fatty acid-conjugated gnrh derivatives and pharmaceutical compositions containing same
WO2020210376A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
WO2020223177A1 (en) 2019-04-29 2020-11-05 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
US20220195059A1 (en) 2019-04-30 2022-06-23 Instituto de Medicina Molecular João Lobo Antunes Rank Pathway Inhibitors in Combination with CDK Inhibitors
AU2020303986A1 (en) 2019-06-24 2021-12-09 Amgen Inc. Inhibition of SIRP-gamma for cancer treatment
JP2022546700A (en) 2019-08-30 2022-11-07 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Copper-ATSM for the treatment of neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
EP4281187A1 (en) 2021-01-20 2023-11-29 Bioentre LLC Ctla4-binding proteins and methods of treating cancer
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (en) * 1983-09-23 1987-07-15 Debiopharm Sa PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF HORMONDEPENDENT DISEASES.
DE3414595A1 (en) * 1984-04-18 1985-10-31 Hoechst Ag, 6230 Frankfurt USE OF GONADOLIBERIN AND GONADOLIBERINAGONISTS FOR TREATING CLIMATE COMPLAINTS
US4540513A (en) * 1984-09-25 1985-09-10 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Decapeptide having gonadotropin releasing activity
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
IT1243390B (en) * 1990-11-22 1994-06-10 Vectorpharma Int PHARMACEUTICAL COMPOSITIONS IN THE FORM OF PARTICLES SUITABLE FOR THE CONTROLLED RELEASE OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PROCEDURE FOR THEIR PREPARATION.
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
AU3388597A (en) * 1996-06-13 1998-01-07 University Of Cape Town Human type ii gonadotropin-releasing hormone receptor

Also Published As

Publication number Publication date
KR20010089538A (en) 2001-10-06
PL348575A1 (en) 2002-06-03
RU2233170C2 (en) 2004-07-27
HUP0104943A3 (en) 2002-08-28
AU1573200A (en) 2000-06-19
NO20012636D0 (en) 2001-05-29
WO2000032218A1 (en) 2000-06-08
EE200100293A (en) 2002-08-15
JP2002531411A (en) 2002-09-24
GB9826662D0 (en) 1999-01-27
TR200102273T2 (en) 2001-12-21
GB2344287A (en) 2000-06-07
HRP20010421A2 (en) 2002-06-30
IL143496A0 (en) 2002-04-21
CA2353798A1 (en) 2000-06-08
ZA200104530B (en) 2002-06-04
BR9915943A (en) 2001-08-21
CZ20011893A3 (en) 2002-05-15
AU770676B2 (en) 2004-02-26
NO20012636L (en) 2001-07-12
SK7552001A3 (en) 2002-02-05
EP1140133A1 (en) 2001-10-10
CN1332635A (en) 2002-01-23
MXPA01005543A (en) 2003-07-14
NZ511984A (en) 2002-11-26

Similar Documents

Publication Publication Date Title
HUP0104943A2 (en) Controlled release formulation comprising gnrh-ii and its use
EG24198A (en) Extended release formulation
HUP0103267A2 (en) Glyphosate formulation and use thereof
HRP20060251B1 (en) Substituted oxasolidinones and their use
HUP0104270A3 (en) Herbicidal composition and use thereof
HK1042084B (en) Substituted benzimidazoles and their preparation and use
AU4161899A (en) Radiotherapeutical device and use thereof
ZA982478B (en) Compounds their use and preparation
GB9813271D0 (en) Composition and use
GB0101035D0 (en) Formulation and use thereof
HRP20000213B1 (en) Extended release formulation
HUP0103636A3 (en) 2-methyl-thieno-benzodiazepine formulation and its use
HUP0203896A3 (en) Substituted 8-arylquinoline phosphodiesterase-4-inhibitors and use thereof
HUP0103845A3 (en) Disinfecting composition and its use
IL145715A0 (en) Formulation arrays and use thereof
HUP0003840A3 (en) Controlled released medical formulation
HUP0103473A3 (en) Phosphoglycolipid and methods for its use
GB9811168D0 (en) Direct hair-colouring compositions and the use thereof
EG22491A (en) Rest-breaking composition and use thereof
HUP0102683A3 (en) Coatings agent and the use thereof
HUP0104723A3 (en) New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins and their use
ZA9711047B (en) Formulation and use.
AU3432900A (en) Colouring agent and the use thereof
GB9911606D0 (en) Composition and use
GB9929581D0 (en) Comjpositions and their use